The World's Largest Healthcare Event -- tHIS Opens to Record Breaking Crowds in Shanghai

  • tHIS,Healthcare Event,API China

SHANGHAI, May 19, 2015. The 2015 Health Industry Summit (tHIS), an event that is predicted to transform the Chinese healthcare industry sector, opened to huge crowds on May 15, with over 210,000 visitors from 150 countries in attendance.

Held at the brand new National Convention & Exhibition Center in Shanghai, tHIS is a large-scale healthcare event that combines China's three top medical equipment and pharmaceutical exhibitions CMEF, PHARMCHINA and API China into one mega healthcare event, in doing so completing the entire value chain for the health industry.

The exhibition occupies a total area of 290,000 sqm of exhibition space and showcases the latest cutting edge medical equipment and equipment manufacturing solutions, pharmaceutical formulations and ingredients, manufacturing technologies, natural health and nutrition products from over 6,800 exhibitors.

Well-known healthcare equipment giants like GE, SIEMENS, Philips, Mindray, and United Imaging had specially designed stands that served as a backdrop for the launch of the hundreds of new to market products, with GE Healthcare unveiling its Revolution CT imaging series, Mindray, with its flexible POC ultrasound system 'mobiEye 700', and ContextVision with GOPICE 2.0 software for imaging among a flurry of launch activities. Global Senior Vice President of GE/ President and CEO of GE China Ms. Rachel Duan Shares her view on the event's success: "Medical & healthcare equipment manufacturers highly value this platform, all bringing with them the latest and best technology to showcase. All the leading companies in the industry are here, all of the top industry talents are here, there lies the explosive popularity of the event."

Meanwhile, anticipating a huge turnout and with a focus on APIs and formulations, China's top pharmaceutical manufacturers and distributors were ready to welcome tens of thousands of domestic and international buyers, while fast-growing market segments such as natural health and nutritional products represented by Natural Health and Nutrition China have seen participation double in size, and the medical device manufacturing show ICMD has seen unprecedented 300% growth in exhibitor participation.

Organizer Reed Sinopharm, a joint venture between the world's leading event organizer Reed Exhibitions and China's leading state-owned pharmaceutical group Sinopharm, used their combined strength of international networks and industry connectivity to write a new chapter for China's healthcare industry, as it transforms from localized industry developments into a maturing market with global reach.

According to a state-issued strategic whitepaper in 2013, China expects the total market size of its health sector to triple to a massive USD 1.2 trillion by 2020. This growth potential in China is partly attributable to its growing ageing population, expected to account for more than 30% of the total by 2050. This coupled with increasing urbanization and the further loosening of the one-child policy will ensure a boom in the birth rate, putting the current health system and hospital facilities under strain.

Furthermore, the new top level investment forum - Healthcare China heads a grand list of 107 conferences which completes the expo and conference mix, covering all the key fields and industry topics, with major conferences including the China Integrated Medical Imaging Summit, Asian Nuclear Medicine Academic Forum and Sino-Europe Pharmaceutical Forum.

Reed Sinopharm commented that tHIS will be held annually in Shanghai every spring and the event is anticipated to become the key platform to define the future trends of the healthcare sector in China and the world.

This link:

The ChemCD compiler finishing, shall not be reproduced without permission, for reprint please indicate the source。

comments powered by Disqus


Related News

Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence

Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bezlotoxumab, an investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence.

Sanofi and Regeneron Announce Sarilumab Biologics License Application Accepted for Review by US FDA

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for sarilumab.

First data backs efficacy of BMS' novel HIV drug

A Bristol-Myers Squibb (BMS) drug that causes immature HIV particles to be released from cells early, interrupting their lifecycle, has cleared a proof-of-concept study.

EU Rules Could Restrict Genetic Testing

Genetic testing describes the application of laboratory methods to look at a person’s genes (the inherited DNA instructions). Genetic tests can be used to diagnose a genetic condition; screen for a risk of developing a particular health problems; for the selection of treatments; or to assess responses to treatments.

CHMP adopts positive opinion of Edurant in adolescents with HIV-1

The CHMP has adopted a positive opinion recommending a change to the terms of the marketing authorisation for Janssen’s Edurant (rilpivirine) in the EU to extend the indication to adolescent patients aged 12 to <18 years with human immunodeficiency virus-1 (HIV-1) infection

FDA finds mystery 'deficiencies' with Neos' long-acting Ritalin on the eve of approval

Neos Therapeutics got an ominous note from the FDA just weeks ahead of the expected approval date for its long-acting ADHD treatment, clouding the future of the company's lead asset.

Pfizer's once-failed cancer drug wins the FDA's 'breakthrough' tag

Pfizer has found new hope for a former pipeline standout, picking up the FDA's coveted breakthrough therapy designation for a Phase III reclamation project in oncology.